Sagespring Wealth Partners LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,646 shares of the medical research company's stock, valued at approximately $913,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Howard Capital Management Inc. raised its stake in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after buying an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after acquiring an additional 56 shares during the last quarter. Cypress Wealth Services LLC boosted its position in shares of IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after purchasing an additional 57 shares in the last quarter. Harbor Investment Advisory LLC grew its stake in shares of IQVIA by 4.7% in the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after purchasing an additional 58 shares during the last quarter. Finally, Magnolia Capital Advisors LLC lifted its stake in IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after purchasing an additional 74 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Stock Performance
Shares of IQV stock traded down $4.78 during trading hours on Friday, reaching $143.66. 3,302,597 shares of the company's stock were exchanged, compared to its average volume of 1,403,069. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The business has a fifty day moving average price of $177.57 and a 200-day moving average price of $197.47. The stock has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have commented on IQV shares. Morgan Stanley upped their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Finally, Barclays reissued an "equal weight" rating and issued a $170.00 price target (down from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Six analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus price target of $241.50.
Get Our Latest Analysis on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
